tirzepatide mastery course
Unit 2 of 12

Molecular Architecture

39 amino acids, two Aib residues, and a C20 fatty acid tail engineered for once-weekly dosing

Engineered for Dual Activation

Tirzepatide is not a natural hormone -- it is a 39-amino-acid peptide engineered by Eli Lilly to activate both the GIP and GLP-1 receptors from a single molecule. Its backbone is derived from the native GIP sequence, but key substitutions -- including two alpha-aminoisobutyric acid (Aib) residues and a C20 fatty diacid side chain -- give it GLP-1 receptor activity and a half-life long enough for once-weekly injection. In this unit you'll see exactly how each structural element contributes to tirzepatide's dual agonist profile.

Explore the Molecular Structure

Interact with tirzepatide's 39-amino-acid chain to see how each region and modification contributes to receptor engagement.

interactive molecular structure explorer
39
amino acids in the tirzepatide peptide chain
~5 days
elimination half-life (113 hours) via albumin binding
5x
weaker GLP-1R affinity vs native GLP-1 (deliberate imbalance)
>99%
protein-bound in circulation via c20 fatty diacid at lys20
single molecule, not a combination. tirzepatide is one continuous 39-amino-acid chain engineered so that different regions activate both GIP and GLP-1 receptors simultaneously. it contains two non-natural amino acids (aib) that cannot be made by standard cellular machinery, which is why it must be produced by chemical peptide synthesis rather than recombinant expression.

key terms for this unit

A alpha-aminoisobutyric acid (aib) structural modification
a non-natural amino acid placed at positions 2 and 13 in tirzepatide. the aib at position 2 sterically blocks the DPP-4 cleavage site, preventing rapid enzymatic degradation. the aib at position 13 stabilizes the alpha-helical conformation.
C c20 fatty diacid pharmacokinetic modification
a 1,20-eicosanedioic acid conjugated to lysine at position 20 via a mini-peg linker. enables high-affinity binding to human serum albumin, extending the half-life to approximately 5 days for once-weekly dosing.
B biased agonism pharmacology
preferential activation of one signaling pathway over another at the same receptor. tirzepatide favors the cAMP pathway over beta-arrestin recruitment at the GLP-1 receptor, reducing receptor internalization.
D DPP-4 enzyme
dipeptidyl peptidase-4, the enzyme that rapidly degrades native GIP and GLP-1, giving them plasma half-lives of only a few minutes. the aib substitution at position 2 blocks this cleavage site.
U unimolecular dual agonist drug classification
a single molecule that activates two different receptors. tirzepatide is the first-in-class unimolecular dual GIP/GLP-1 receptor agonist, delivering both receptor-activating functions from one injection.

molecular architecture -- the simple version

what tirzepatide is made of and why each piece matters.

tirzepatide is a chain of 39 amino acids (the building blocks of all proteins) designed by Eli Lilly to do something no natural hormone can: activate two different receptors from a single molecule. the chain is based on the natural GIP hormone but has been modified so that parts of it also fit the GLP-1 receptor. two non-natural amino acids called Aib are swapped in at positions 2 and 13 -- position 2 blocks the enzyme (DPP-4) that would normally destroy the peptide in minutes, and position 13 stabilizes the chain's shape. a fatty acid tail attached at position 20 lets the peptide hitch a ride on albumin in the blood, extending its life to about five days so patients only need one injection per week.

A advanced: Aib substitutions and DPP-4 resistance term
alpha-aminoisobutyric acid (Aib) is a non-natural amino acid that cannot be incorporated by standard ribosomal translation, which is why tirzepatide must be produced by chemical peptide synthesis. the Aib at position 2 sterically blocks the DPP-4 cleavage site -- the enzyme that gives native GIP and GLP-1 plasma half-lives of only a few minutes. the Aib at position 13 stabilizes the alpha-helical conformation of the peptide, providing additional proteolytic resistance. together, these two substitutions are the primary reason tirzepatide survives in circulation long enough to be therapeutically useful.
advanced: C20 fatty diacid and albumin binding
the lysine at position 20 is conjugated to a 1,20-eicosanedioic acid (C20 fatty diacid) through a linker composed of one gamma-glutamic acid and two mini-PEG spacers. this lipid modification enables high-affinity binding to human serum albumin, with greater than 99% of circulating tirzepatide bound to protein at any given time. the albumin complex creates a slow-release depot in the bloodstream, producing an elimination half-life of approximately 113 hours (about 5 days) and reaching steady state after roughly 4 weeks of once-weekly dosing.
advanced: imbalanced and biased receptor engagement
tirzepatide is an imbalanced dual agonist: it binds the GIP receptor with approximately equal affinity to native GIP (full agonism) but binds the GLP-1 receptor with about 5-fold weaker affinity. this imbalance is deliberate. at the GLP-1 receptor, tirzepatide also exhibits biased agonism -- it preferentially activates the Gs/cAMP pathway over beta-arrestin recruitment, reducing receptor internalization. in head-to-head trials, tirzepatide delivered approximately 47% greater relative weight loss than semaglutide, a difference too large to explain by receptor affinity alone.